Researchers discover a gene family strongly implicated in the development of liver cancer

NewsGuard 100/100 Score

In a comprehensive analysis of human gene activation data, researchers from the Centenary Institute have discovered that the dipeptidyl peptidase-4 (DPP4) gene family is strongly implicated in the development of human hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

Researchers discover a gene family strongly implicated in the development of liver cancer
Dr Hui Emma Zhang. Image Credit: Centenary Institute

Reported in the journal ‘Cancers’, the research suggests that the DPP4 gene family and the four enzymes that it contains should be further studied to support potential new therapeutic approaches to fighting tumors found in the liver.

“In this study we interrogated a number of publicly accessible human gene databases including The Cancer Genome Atlas to identify cancers associated with the DPP4 gene family,” said Dr Hui Emma Zhang, researcher in the Centenary Institute’s Liver Enzymes in Metabolism and Inflammation Program and co-senior author on the paper.

We were focused on the four enzymes of the DPP4 gene family– DPP4, DPP8, DPP9 and fibroblast activation protein (FAP). The role of the DPP9 enzyme was of particular interest as it hadn’t been studied previously with regard to liver cancer in humans."

Dr Hui Emma Zhang, Researcher in Liver Enzymes in Metabolism and Inflammation Program, Centenary Institute

Results from the data mining and subsequent analysis undertaken by the research team were revealing.

An association between high levels of the DPP9 enzyme and uterine and lung cancer was found suggesting that further investigatory work in both areas was required.

Elevated levels of DPP9, DPP4, FAP and DPP8 enzymes were also discovered in liver tumors and critically, were associated with poor survival rates in HCC patients.

Our analysis indicates that high levels of all enzymes of the DPP4 family occur in liver cancers, which encourages us to target these enzymes as a possible new therapeutic approach to tackling the disease. With liver cancer incidence and mortality rates in Australia rapidly increasing new treatment options are urgently required both to improve and to save people’s lives.”

Dr Hui Emma Zhang

Over 2,000 Australians die each year from liver cancer. The five year survival rate for liver cancer is below 20%.

Source:
Journal reference:

Huang, J.C., et al. (2021) DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. Cancers. doi.org/10.3390/cancers13071637.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Experimental gene therapy shows promise for treating herpes infections